Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15546957 | 0.98 | EPHX1 (0.67) | EPHX1POLBGABRPGABRDGABRA1 | |
| Bicarbonate SCHEMBL28207579 | 0.91 | EPHX1 (0.59) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL2324691 | 0.91 | EPHX1 (0.62) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL3614519 | 0.91 | EPHX1 (0.62) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL22233774 | 0.91 | EPHX1 (0.62) | EPHX1POLBGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL14688322 | 0.89 | EPHX1 (0.60) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL28797537 | 0.87 | EPHX1 (0.54) | EPHX1POLBGABRPGABRDGABRA1 | |
| Cyclohexanol SCHEMBL9330386 | 0.86 | EPHX1 (0.61) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL1749149 | 0.86 | — | — | |
| SCHEMBL512691 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102224153-B | Substituted imidazo [1,2-B ] pyridazine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC | 2014-04-30 | — | — | CN | claimed |
| EP-1102789-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008046-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | claimed |
| WO-2026103730-A1 | DIAZAHETEROCYCLIC DERIVATIVE OF PYRIDOARYL GROUP HAVING KAPPA RECEPTOR ANTAGONISTIC ACTIVITY AND COMPOSITION THEREOF, AND USE | 江苏恩华药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | HANMI PHARM. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| WO-2025233682-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| EP-4624464-A1 | PYRIDINE POLYCYCLIC COMPOUND INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-5246939-A | Antiadrenergic systems for lower urinary apparatus | SYNTHELABO (FR) | 1993-09-21 | — | — | US | disclosed |
| US-5244894-A | Treating disorders involving hyperactivity of the alpha 1-adrenergic system in lower urinary tract | SYNTHELABO | 1993-09-14 | — | — | US | disclosed |
| US-5189036-A | Cardiovascular agents; class III antiarrhythmic agents | SCHERING AG (DE) | 1993-02-23 | — | — | US | disclosed |
| EP-0522914-A1 | 2-Piperidinylpyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1993-01-13 | — | — | EP | disclosed |
| CN-1067885-A | 2-aminopyrimidine-4-carboxamides derivatives and method for making and medical applications | SYNTHELABO (FR) | 1993-01-13 | — | — | CN | disclosed |
| EP-0520882-A1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1992-12-30 | — | — | EP | disclosed |
| EP-0520883-A1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1992-12-30 | — | — | EP | disclosed |
| EP-0467325-A2 | Carbostyril derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082847-A | Antiarrhythmia | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | KDM1A, KDM1B, KDM2A | EPHX1 1307/4885POLB 2481/4885GABRP 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.